IL318752A - שילובים נגד סרטן הכוללים תרפיה ממוקדת - Google Patents
שילובים נגד סרטן הכוללים תרפיה ממוקדתInfo
- Publication number
- IL318752A IL318752A IL318752A IL31875225A IL318752A IL 318752 A IL318752 A IL 318752A IL 318752 A IL318752 A IL 318752A IL 31875225 A IL31875225 A IL 31875225A IL 318752 A IL318752 A IL 318752A
- Authority
- IL
- Israel
- Prior art keywords
- targeted therapy
- anti cancer
- cancer combinations
- combinations
- targeted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22190139 | 2022-08-12 | ||
| PCT/EP2023/072324 WO2024033537A1 (en) | 2022-08-12 | 2023-08-11 | Combination of anticancer agents comprising a bifunctional compound with g12d mutant kras inhibitory activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL318752A true IL318752A (he) | 2025-04-01 |
Family
ID=83080925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL318752A IL318752A (he) | 2022-08-12 | 2023-08-11 | שילובים נגד סרטן הכוללים תרפיה ממוקדת |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP4568674A1 (he) |
| JP (1) | JP7733274B1 (he) |
| KR (1) | KR20250044876A (he) |
| CN (1) | CN119677517A (he) |
| AR (1) | AR130191A1 (he) |
| AU (1) | AU2023322689A1 (he) |
| CA (1) | CA3264277A1 (he) |
| CL (1) | CL2025000383A1 (he) |
| CO (1) | CO2025002794A2 (he) |
| IL (1) | IL318752A (he) |
| MX (1) | MX2025001671A (he) |
| TW (1) | TW202412809A (he) |
| WO (1) | WO2024033537A1 (he) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024337913A1 (en) | 2023-09-08 | 2026-03-26 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015508414A (ja) | 2012-01-12 | 2015-03-19 | イエール ユニバーシティ | E3ユビキチンリガーゼによる標的タンパク質および他のポリペプチドの分解増強のための化合物および方法 |
| CN119591582A (zh) | 2014-04-14 | 2025-03-11 | 阿尔维纳斯运营股份有限公司 | 基于酰亚胺的蛋白水解调节剂和相关使用方法 |
| WO2016049565A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Compositions and methods for inhibition of ras |
| WO2016049568A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Methods and compositions for inhibition of ras |
| US10822312B2 (en) | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| JOP20190186A1 (ar) | 2017-02-02 | 2019-08-01 | Astellas Pharma Inc | مركب كينازولين |
| CN119569702A (zh) | 2018-04-04 | 2025-03-07 | 阿尔维纳斯运营股份有限公司 | 蛋白水解调节剂及相关使用方法 |
| CA3102996A1 (en) | 2018-07-20 | 2020-01-23 | Dana-Farber Cancer Institute, Inc. | Degraders that target proteins via keap1 |
| JP2021176820A (ja) | 2018-07-31 | 2021-11-11 | アステラス製薬株式会社 | キナゾリン化合物を有効成分とする医薬組成物 |
| WO2021106231A1 (en) | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
| EP4132655A1 (en) | 2020-04-06 | 2023-02-15 | Arvinas Operations, Inc. | Compounds and methods for targeted degradation of kras |
| EP4175947A4 (en) | 2020-06-30 | 2024-07-03 | InventisBio Co., Ltd. | QUINAZOLINE COMPOUNDS, THEIR PREPARATION PROCESSES AND THEIR USES |
| WO2022105855A1 (en) | 2020-11-20 | 2022-05-27 | Jacobio Pharmaceuticals Co., Ltd. | Kras g12d inhibitors |
| US20240140957A1 (en) * | 2021-01-08 | 2024-05-02 | Beigene Switzerland Gmbh | Bridged compounds as kras g12d inhibitor and degrader and the use thereof |
| WO2022148421A1 (en) * | 2021-01-08 | 2022-07-14 | Beigene, Ltd. | Bridged compounds as kras g12d inhibitor and degrader and the use thereof |
| CA3203205A1 (en) | 2021-01-19 | 2022-07-28 | Mandar Ramesh Bhonde | Pharmaceutical combinations of sos1 inhibitors for treating and/or preventing cancer |
| CN116848120B (zh) * | 2021-02-15 | 2026-02-13 | 安斯泰来制药株式会社 | 用于诱导g12d突变kras蛋白分解的喹唑啉化合物 |
| PL4293025T3 (pl) * | 2021-02-15 | 2026-02-16 | Astellas Pharma Inc. | Kompozycja 4-aminochinazoliny |
| WO2023119677A1 (en) | 2021-12-24 | 2023-06-29 | Astellas Pharma Inc. | Pharmaceutical composition comprising a quinazoline compound |
-
2023
- 2023-08-11 TW TW112130325A patent/TW202412809A/zh unknown
- 2023-08-11 AR ARP230102132A patent/AR130191A1/es unknown
- 2023-08-11 KR KR1020257004512A patent/KR20250044876A/ko active Pending
- 2023-08-11 EP EP23757233.4A patent/EP4568674A1/en active Pending
- 2023-08-11 CN CN202380057900.7A patent/CN119677517A/zh active Pending
- 2023-08-11 CA CA3264277A patent/CA3264277A1/en active Pending
- 2023-08-11 AU AU2023322689A patent/AU2023322689A1/en active Pending
- 2023-08-11 WO PCT/EP2023/072324 patent/WO2024033537A1/en not_active Ceased
- 2023-08-11 JP JP2025501550A patent/JP7733274B1/ja active Active
- 2023-08-11 IL IL318752A patent/IL318752A/he unknown
-
2025
- 2025-02-10 MX MX2025001671A patent/MX2025001671A/es unknown
- 2025-02-10 CL CL2025000383A patent/CL2025000383A1/es unknown
- 2025-03-05 CO CONC2025/0002794A patent/CO2025002794A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024033537A1 (en) | 2024-02-15 |
| TW202412809A (zh) | 2024-04-01 |
| MX2025001671A (es) | 2025-03-07 |
| KR20250044876A (ko) | 2025-04-01 |
| CL2025000383A1 (es) | 2025-04-11 |
| AR130191A1 (es) | 2024-11-13 |
| AU2023322689A1 (en) | 2025-03-20 |
| JP2025530624A (ja) | 2025-09-17 |
| CA3264277A1 (en) | 2024-02-15 |
| EP4568674A1 (en) | 2025-06-18 |
| CO2025002794A2 (es) | 2025-03-27 |
| CN119677517A (zh) | 2025-03-21 |
| JP7733274B1 (ja) | 2025-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4010081A4 (en) | POLYTHERAPY FOR THE TREATMENT OF CANCER | |
| ZA202106392B (en) | Therapeutic rna for prostate cancer | |
| IL307964A (he) | טיפול משולב לטיפול בסרטן | |
| PT4225297T (pt) | Terapia de combinação para o tratamento de cancro | |
| IL300171A (he) | טיפול משולב נגד סרטן | |
| IL304436A (he) | טיפול בסרטן | |
| IL316017A (he) | טיפול משולב לטיפול בסרטן | |
| IL316016A (he) | טיפול משולב לטיפול בסרטן | |
| GB202301902D0 (en) | Combination therapy for cancer | |
| CA3264277A1 (en) | Combination of anticancer agents comprising a bifunctional compound having KRAS mutant G12D inhibitory activity | |
| IL288178A (he) | טיפול משולב gmci ו– ddri לטיפול בסרטן | |
| GB202218395D0 (en) | Cancer therapy | |
| IL317573A (he) | טיפול משולב לטיפול בסרטן | |
| IL316019A (he) | טיפול משולב לטיפול בסרטן | |
| EP4251133C0 (en) | COMBINED CANCER THERAPY | |
| EP4313029A4 (en) | COMBINATION THERAPY FOR CANCER TREATMENT | |
| GB202001963D0 (en) | Cancer therapy | |
| AU2022903962A0 (en) | Targeted combination cancer therapy | |
| GB202318158D0 (en) | Cancer therapy | |
| GB202302018D0 (en) | Cancer therapy | |
| GB202212918D0 (en) | Cancer therapy | |
| GB202116680D0 (en) | Combination therapy for cancer | |
| GB202208893D0 (en) | Combination therapy for cancer | |
| IL305777A (he) | שילוב רפואי לטיפול בסרטן | |
| GB202000984D0 (en) | Cancer therapy |